scholarly journals Clinically Approved MRI Contrast Agents as Imaging Labels for a Porous Iron‐Based MOF Nanocarrier: A Systematic Investigation in a Clinical MRI Setting

2019 ◽  
Vol 3 (1) ◽  
pp. 1900126 ◽  
Author(s):  
Konstantin Böll ◽  
Andreas Zimpel ◽  
Olaf Dietrich ◽  
Stefan Wuttke ◽  
Michael Peller
2020 ◽  
Vol 13 (10) ◽  
pp. 296
Author(s):  
Friederike Reeßing ◽  
Sèvrin E. M. Huijsse ◽  
Rudi A. J. O. Dierckx ◽  
Ben L. Feringa ◽  
Ronald J.H. Borra ◽  
...  

Thanks to its innocuousness and high spatiotemporal resolution, light is used in several established and emerging applications in biomedicine. Among them is the modulation of magnetic resonance imaging (MRI) contrast agents’ relaxivity with the aim to increase the sensitivity, selectivity and amount of functional information obtained from this outstanding whole-body medical imaging technique. This approach requires the development of molecular contrast agents that show high relaxivity and strongly pronounced photo-responsiveness. To this end, we report here the design and synthesis of a light-activated MRI contrast agent, together with its evaluation using UV–vis spectroscopy, Fast Field Cycling (FFC) relaxometry and relaxometric measurements on clinical MRI scanners. The high relaxivity of the reported agent changes substantially upon irradiation with light, showing a 17% decrease in relaxivity at 0.23T upon irradiation with λ = 400 nm (violet) light for 60 min. On clinical MRI scanners (1.5T and 3.0T), irradiation leads to a decrease in relaxivity of 9% and 19% after 3 and 60 min, respectively. The molecular design presents an important blueprint for the development of light-activatable MRI contrast agents.


2005 ◽  
Vol 12 (5) ◽  
pp. S77-S78
Author(s):  
Hisataka Kobayashi ◽  
Sang-Kyung Jo ◽  
Satomi Kawamoto ◽  
Martin W. Brechbiel ◽  
Martin J. Lizak ◽  
...  

2020 ◽  
Vol 14 (4) ◽  
pp. 504-532 ◽  
Author(s):  
Emily J. Guggenheim ◽  
Joshua Z. Rappoport ◽  
Iseult Lynch

2017 ◽  
Vol 24 (5) ◽  
pp. 470-482 ◽  
Author(s):  
Nicolas Alcaraz ◽  
Ben J. Boyd

Author(s):  
Anton Popov ◽  
Maxim Artemovich Abakumov ◽  
Irina Savintseva ◽  
Artem Ermakov ◽  
Nelly Popova ◽  
...  

Gd-based complexes are widely used as magnetic resonance imaging (MRI) contrast agents. The safety of previously approved contrast agents is questionable and is being re-assessed. The main causes of concern...


2021 ◽  
Vol 379 (4) ◽  
Author(s):  
Ashish Avasthi ◽  
Carlos Caro ◽  
Esther Pozo-Torres ◽  
Manuel Pernia Leal ◽  
María Luisa García-Martín

A correction to this paper has been published: https://doi.org/10.1007/s41061-021-00340-y


Nano Letters ◽  
2021 ◽  
Vol 21 (7) ◽  
pp. 2793-2799
Author(s):  
Jingfang Zhang ◽  
Zhenghan Di ◽  
Husheng Yan ◽  
Yuliang Zhao ◽  
Lele Li

2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.


Sign in / Sign up

Export Citation Format

Share Document